Literature DB >> 19089685

How do mesenchymal stromal cells exert their therapeutic benefit?

E M Horwitz1, M Dominici.   

Abstract

In recent years mesenchymal stromal cells (MSC) have emerged as a major new form of cell therapy. While the original perception was that MSC were stem/progenitor cells with the potential to contribute to the regeneration of tissue, more recent data suggest that the principal mechanism of MSC activity is through the release of soluble mediators that elicit the observed biologic response. Future studies are needed to identify more completely the spectrum of therapeutic applications and delineate better the associated molecular and cellular mechanisms.

Mesh:

Substances:

Year:  2008        PMID: 19089685     DOI: 10.1080/14653240802618085

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  49 in total

1.  Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.

Authors:  Won Sik Lee; Yasuhiro Suzuki; Scott S Graves; Mineo Iwata; G M Venkataraman; Marco Mielcarek; Laura J Peterson; Susumu Ikehara; Beverly Torok-Storb; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-10       Impact factor: 5.742

2.  Bone marrow cells are a source of undifferentiated cells to prevent Sjögren's syndrome and to preserve salivary glands function in the non-obese diabetic mice.

Authors:  Saeed Khalili; Younan Liu; Yoshinori Sumita; Ola M Maria; David Blank; Sharon Key; Eva Mezey; Simon D Tran
Journal:  Int J Biochem Cell Biol       Date:  2010-08-21       Impact factor: 5.085

3.  Building bone from blood vessels.

Authors:  Edwin M Horwitz
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

4.  Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model.

Authors:  Juha P Laurila; Lilja Laatikainen; Maria D Castellone; Parul Trivedi; Jari Heikkila; Ari Hinkkanen; Peiman Hematti; Mikko O Laukkanen
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

5.  A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression.

Authors:  Debra D Bloom; John M Centanni; Neehar Bhatia; Carol A Emler; Diana Drier; Glen E Leverson; David H McKenna; Adrian P Gee; Robert Lindblad; Derek J Hei; Peiman Hematti
Journal:  Cytotherapy       Date:  2014-11-21       Impact factor: 5.414

Review 6.  Stem cell therapy: an exercise in patience and prudence.

Authors:  Huan-Ting Lin; Makoto Otsu; Hiromitsu Nakauchi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-05       Impact factor: 6.237

Review 7.  In situ tissue regeneration: chemoattractants for endogenous stem cell recruitment.

Authors:  Wendy S Vanden Berg-Foels
Journal:  Tissue Eng Part B Rev       Date:  2013-07-11       Impact factor: 6.389

Review 8.  Identification and Characterization of Human Endometrial Mesenchymal Stem/Stromal Cells and Their Potential for Cellular Therapy.

Authors:  Saeedeh Darzi; Jerome A Werkmeister; James A Deane; Caroline E Gargett
Journal:  Stem Cells Transl Med       Date:  2016-05-31       Impact factor: 6.940

9.  Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages.

Authors:  Jaehyup Kim; Peiman Hematti
Journal:  Exp Hematol       Date:  2009-09-20       Impact factor: 3.084

10.  A diabetic milieu promotes OCT4 and NANOG production in human visceral-derived adipose stem cells.

Authors:  P Dentelli; C Barale; G Togliatto; A Trombetta; C Olgasi; M Gili; C Riganti; M Toppino; M F Brizzi
Journal:  Diabetologia       Date:  2012-10-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.